refludan and Stroke

refludan has been researched along with Stroke* in 2 studies

Reviews

1 review(s) available for refludan and Stroke

ArticleYear
New anticoagulant agents: direct thrombin inhibitors.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Decades of research have been devoted to developing effective, safe, and convenient anticoagulant agents. In recent years, much emphasis has been placed on the development of direct thrombin inhibitors (DTIs) that offer benefits over agents like heparin and warfarin including the inhibition of both circulating and clot-bound thrombin; a more predictable anticoagulant response, because they do not bind to plasma proteins and are not neutralized by platelet factor 4; lack of required cofactors, such as antithrombin or heparin cofactor II; inhibiting thrombin-induced platelet aggregation; and absence of induction of immune-mediated thrombocytopenia. Various injectable DTIs are currently available and used for many indications. In addition, research is now focusing on oral DTIs that seem promising and offer various advantages, such as oral administration, predictable pharmacokinetics and pharmacodynamics, a broad therapeutic window, no routine monitoring, no significant drug interactions, and fixed-dose administration.

    Topics: Anticoagulants; Arginine; Atrial Fibrillation; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Half-Life; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Stroke; Sulfonamides; Thrombin

2008

Other Studies

1 other study(ies) available for refludan and Stroke

ArticleYear
Heparin-induced thrombosis with a normal platelet count.
    Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2007, Volume: 9, Issue:1

    Heparin is commonly used in the intensive care unit for preventing and treating thromboembolic disease. One of its more significant complications is heparin-induced thrombocytopenia (HIT), an immune-mediated disorder which can provoke an extreme prothrombotic state. We describe an unusual presentation of HIT, where thrombocytopenia was absent.

    Topics: Adult; Anticoagulants; Calcitonin; Female; Follow-Up Studies; Heparin; Hirudins; Humans; Intensive Care Units; Partial Thromboplastin Time; Platelet Count; Protein Precursors; Recombinant Proteins; Stroke; Thrombocytopenia; Thrombosis; Time Factors; Tomography, X-Ray Computed

2007